此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (US20020018767) Anti-cancer cellular vaccine
注:相关文本通过自动光符识别流程生成。凡涉及法律问题,请以 PDF 版本为准

Claims

1. A method of eliciting an anti-tumor immune response in a patient comprising:
isolating cancerous cells from a patient;
transfecting said cancerous cells with an expression vector system comprising a DNA molecule encoding IL-12 and a costimulatory molecule operably linked to a promoter capable of directing expression of said DNA molecule in said cancerous cells;
incubating said transfected cells under conditions whereby the IL-12 and the costimulatory molecules are expressed; and
eliciting an anti-tumor immune response in the patient by injecting said transfected cells into the patient.
2. The method according to claim 1 including irradiating the cancerous cells to prevent replication of the cancerous cells prior to injection of the cancerous cells into the patient.
3. The method according to claim 1 wherein IL-12 is a single gene fusion of p35 and p40.
4. The method according to claim 1 wherein the costimulatory molecule is B7-1.
5. A method of vaccinating an individual comprising:
providing cancerous cells isolated from a donor;
transfecting said cancerous cells with an expression vector system comprising a DNA molecule encoding IL-12 and a costimulatory molecule operably linked to a promoter capable of directing expression of said DNA molecule in said cancerous cells;
incubating said transfected cells under conditions whereby the IL-12 and the costimulatory molecules are expressed;
isolating naive T cells from the individual;
exposing the T cells to the transfected cancerous cells, thereby activating the T cells;
separating the active T cells from the transfected cancerous cells; and
injecting the activated T cells into the patient.
6. The method according to claim 5 wherein IL-12 is a single gene fusion of p35 and p40.
7. The method according to claim 5 wherein the costimulatory molecule is B7-1.
8. An expression system comprising a DNA molecule encoding IL-12 and a costimulatory molecule operably linked to a promoter.
9. The expression system according to claim 8 wherein the IL-12 comprises a fusion of p35 and p40.
10. The expression system according to claim 8 wherein the costimulatory molecule is selected from the group consisting of: B7-1; B7-2 and CD40L.
11. The expression system according to claim 8 wherein the costimulatory molecule is B7-1.
12. A cancerous cell transfected with the expression system of claim 8.
13. An anti-cancer vaccine comprising the cancerous cell of claim 12 and a suitable excipient.